Materials and Methods
Hep G2 cells were cultured as described previously1).
Human LDL (purchased from Sigma, USA) was used for In Vivo Serum Cholesterol-lowering Effects in
Cholesterol Fed Rabbits Male Japanese white rabbits (9 weeks old) were fed with 0.5% cholesterol containing diet for one week. After grouping the rabbits by body weight and plasma cholesterol level, groups of 5 rabbits were fed with 0.5% cholesterol diet (control) or 0.5% cholesterol diet supplemented with 1 (0.0025%, 0.00025%, 0.000025% and 0.0000025% dosed 1, 0.1, 0.01, 0.001mg/kg/day, respectively) for three weeks. 
Inhibition of Sterol Synthesis in Rats by 1
Single oral administration of compound 1 inhibited rat hepatic sterol synthesis in vivo with an ED50 value at 4.6mg/kg (Fig. 3) . This demonstrates that compound 1 can serve as an effective inhibitor of cholesterol synthesis in vivo.
In Vivo Serum Cholesterol Lowering Effect in
Cholesterol Fed Rabbits
As shown in Fig. 4 , daily dosing of compound 1 reduced serum cholesterol levels in cholesterol fed rabbits at doses of 1 to 0.001mg/kg. In these dosages, 1 did not show any significant toxic effects. In 0.1mg/kg dosed group, one rabbit did not respond to treatment.
Discussion
In this paper, we show the in vitro and in vivo effects of (1) Next we tested the effect of 1 on hepatic sterol synthesis in vivo. As shown in Fig. 3 , single oral administration of compound 1 was shown to inhibit hepatic sterol synthesis in rat dose dependently with an ED50 value of 4.6mg/kg.
Finally daily oral administration of compound 1 reduced serum cholesterol levels in cholesterol fed rabbits without any significant toxicity in vivo (Fig 4) . Especially very low dose, such as 0.01 to 0.001mg/kg/day, multiply administration of FR171456 significantly reduce the serum cholesterol level in cholesterol fed rabbits. Therefore FR171456 and/or FR173945 are expected to have hypolipidemic effect in humans.
